Researchers attending the 16th Annual Meeting of The Society for Neuro-Oncology (SNO) in Orange County, CA gave a promising presentation this week on a brain cancer vaccine in clinical trials.
The trial, called ACT III, was a multi-center, single arm, Phase II clinical trial of rindopepimut (CDX-110), a product of Celldex Therapeutics, in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB), an extremely aggressive brain cancer with a generally poor prognosis.
Rindopepimut targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII), a mutated form of the epidermal growth factor receptor (EGFR), only expressed in cancer cells. This is a transforming oncogene that can directly contribute to the growth of a tumor. It is believed that about one third of all patients with glioblastoma express EGFRvIII.
According to the data in the presentation, rindopepimut appears to nearly double the overall survival times in these patients, from a little over a year to a median OS of just over two years.
Next up for Celldex will be ACT IV, a pivotal, randomized, blinded international Phase III study of rindopepimut.
Source: Celldex Therapeutics
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
